CRMi003-A-2
General
Cell Line |
|
| hPSCreg name | CRMi003-A-2 |
| Cite as: | CRMi003-A-2 (RRID:CVCL_B5S5) |
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines |
CRMi003-A-3 (Proliving, GMNN-mScarletI Reporter) CRMi003-A (NCRM-1, NL-1) UCSFi001-A-12 (AICS-0036-006) MRIi003-A-7 (HK-AAVS1-iCasRx) MRIi003-A-8 (HK-AAVS1-CAG-eGFP-homo) UCSFi001-A-23 (AICS-0054-091) UCSFi001-A-36 (AICS-0036-028) BIHi001-A-1 (iBCRT Cas9v1-3G-Kl.16) MRIi001-A-1 (C6-AAVS1-iCasRx) ICGi021-A-1 (K6-4fpCyto-13) ICGi021-A-2 (K6-4fpCyto-16) ICGi021-A-3 (K6-4fpCyto-19) |
| Last update | 4th November 2021 |
| User feedback | |
Provider |
|
| Generator | Leiden University Medical Center (LUMC) |
| Owner | LUMC hiPSC core facility |
| Distributors | |
| Derivation country | Netherlands |
External Databases |
|
| BioSamples | SAMEA10199970 |
| Cellosaurus | CVCL_B5S5 |
| Wikidata | Q111733136 |
General Information |
|
| Publications |
|
| * Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
|
| Subclone of | |
Donor Information
General Donor Information |
|
| Sex | male |
| Ethnicity | unknown |
Phenotype and Disease related information (Donor) |
|
| Diseases | No disease was diagnosed.
|
| Family history | unknown |
| Is the medical history available upon request? | no |
| Is clinical information available? | no |
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
No
|
External Databases (Donor) |
|
| BioSamples | SAMEA7776418 |
Ethics
Also have a look at the ethics information for the parental line
CRMi003-A
.
| Is there an MTA available for the cell line? | Yes |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? | |
| Are you aware of any constraints on the use or distribution of the cell line from the owner or any parties identified in the query above? | No |
hIPSC Derivation
General |
|
|
The source cell information can be found in the parental cell line
CRMi003-A.
|
|
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Episomal |
| Genes | |
| Is reprogramming vector detectable? |
Unknown |
Vector free reprogramming |
|
| Type of used vector free reprogramming factor(s) |
None
|
Other |
|
| Selection criteria for clones | Colony Morphology |
| Derived under xeno-free conditions |
No |
| Derived under GMP? |
No |
| Available as clinical grade? |
No |
Culture Conditions
| Surface coating | Matrigel/Geltrex |
| Feeder cells |
No |
| Passage method |
Enzyme-free cell dissociation
Gentle Cell Dissociation Reagent
|
| O2 Concentration | 20 % |
| CO2 Concentration | 5 % |
| Medium |
Other medium:
Base medium: StemFlex Medium
Main protein source: Serum concentration: % |
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | No |
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | Yes |
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | No |
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| POU5F1 (OCT-4) |
Yes |
|||||
| NANOG |
Yes |
|||||
| SSEA-4 |
Yes |
Morphology pictures
Differentiation Potency
In vitro directed differentiation
Morphology
Protocol or reference
StemDiff Trilineage Differentiation Kit.pdf
StemDiff Trilineage Differentiation Kit
In vitro directed differentiation
Morphology
Protocol or reference
In vitro directed differentiation
| Marker | Expressed |
| beta-III tubulin |
Yes |
| PAX6 |
Yes |
Morphology
Protocol or reference
Microbiology / Virus Screening |
|
| Mycoplasma | Negative |
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
46,XY
Passage number: 32
Karyotyping method:
G-Banding
|
Other Genotyping (Cell Line) |
|
Genetic Modification
| Genetic modifications not related to a disease |
|
Login to share your feedback, experiences or results with the research community.